Ocrevus
Non-Active SPMS
Indapta Therapeutics, INC.Phase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Non-Active SPMS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Mesna Indapta Therapeutics, INC. | Phase 1 | CC |
Cyclophosphamide Indapta Therapeutics, INC. | Phase 1 | CC |
Same molecule, other indications
Ocrevus is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →